This document relates a composition having an effective amount of a dihydrocinnamate compound for use in the treatment of a skin disorder associated with proteasome activity, wherein the dihydrocinnamate compound is selected from the group consisting of: Ciba® Irganox® 1010； Ciba® Irganox® 1035； Ciba® Irganox® 1076； Ciba® Irganox® 1135； Ciba® Irganox® 245 DW； and analogs thereof wherein one or more of the hydrogen atoms on the phenyl ring in the dihydrocinnamate moiety in the listed compounds can be replaced with a group selected from the selected from the group consisting of a halogen, hydroxyl group, ether group, alkyl group, aryl group, nitro group, cyano group, thiol group, thioester group, amino group, and amido group.
